Epilepsy Development Articles & Analysis
7 news found
Blum, a neurologist by training, is also a seasoned pharmaceutical executive who has secured drug approvals in the U.S., Canada and Europe and designed the first-in human clinical trial of NRTX-1001 for chronic focal epilepsy.” Catherine Priest is the chief development officer at Neurona Therapeutics. ...
The company’s beachhead product, available in Europe, Australia and New Zealand, is for people with absence epilepsy, the most common pediatric epilepsy syndrome causing absence seizures, which mostly look like daydreaming. Yet for the person themselves an absence seizure is a full blackout with no recollection of what happened. People with this type of ...
KT Corporation and NeuroSigma, Inc. jointly announced signing of a memorandum of understanding, forming a strategic partnership to develop and commercialize, inside and outside of Korea, electronic therapies treating neurological and neuropsychological disorders, including ADHD, depression, and epilepsy. NeuroSigma is the developer of the Monarch ...
The prevalence of sleep disorders, epilepsy and cardiovascular disease pose a significant challenge to the US healthcare system. Notably, 70 million Americans suffer from some form of a sleep disorder, 1 in 26 people will develop epilepsy or recurrent seizures during their lifetime, and 48% of all adults in the US have some type of cardiovascular ...
“The goal of our research grants program is to accelerate the development of new therapies and diagnostic devices so that we can get them to people with epilepsy faster, and in a time frame that matters,” says Sonya Dumanis, PhD senior director of Innovation, Epilepsy Foundation. ...
It is estimated that 1 in 100 people have epilepsy, and 1 in 3 people with epilepsy continue to experience uncontrollable and unpredictable seizures despite medication. ...
Flowonix Medical, Inc. and Cerebral Therapeutics, Inc. announced today the successful implant of the fifth patient in the ADDRESS (Australian Direct Drug Administration for Refractory Epilepsy) trial. The jointly developed therapy features a micro-infusion device which tightly controls drug delivery to a region of the brain for patients with medically refractory ...